Want to see PRTCY full AI Analyst Report?
Top Page
PureTech Health
(OTC:PRTCY)
Select Model
Select Model
Rating:47Neutral
Price Target:
$15.50
▼(-3.49% Downside)
Action:Reiterated
Date:08/06/26
The score is held down primarily by weak financial performance (recurring losses and sustained cash burn) and bearish technicals (below major moving averages with negative momentum). Offsetting factors include a relatively low-leverage balance sheet and a cautiously constructive earnings-call outlook with a guided runway through end-2028 and program progress, though external funding dependence remains a key risk.
Positive Factors
Low leverage balance sheet
Low debt (≈5% D/E) provides durable financial flexibility for a development-stage biotech: it reduces refinancing risk, preserves capacity to support clinical programs or opportunistic monetizations, and gives management optionality when structuring collaborations or royalty sales.
Negative Factors
Sustained negative cash generation
Persistently negative operating and free cash flow is a structural weakness: ongoing cash burn erodes liquidity and equity, forcing reliance on external funding or monetizations. Over multiple quarters this constrains investment optionality and raises dilution or asset‑sale risk if inflows underperform expectations.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage balance sheet
Low debt (≈5% D/E) provides durable financial flexibility for a development-stage biotech: it reduces refinancing risk, preserves capacity to support clinical programs or opportunistic monetizations, and gives management optionality when structuring collaborations or royalty sales.
Read all positive factors
PureTech Health (PRTCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$416.76M
Dividend YieldN/A
Average Volume (3M)4.02K
Price to Earnings (P/E)―
Beta (1Y)0.42
Revenue Growth-3.44%
EPS Growth-312.58%
CountryUS
Employees90
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-28.80
Shares Outstanding24,437,502
10 Day Avg. Volume1,390
30 Day Avg. Volume4,023
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.13
Price to Sales (P/S)8.60
P/FCF Ratio-0.47
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.33
Revenue Forecast (FY)$10.30M
PureTech Health Business Overview & Revenue Model
Company Description
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neu...
How the Company Makes Money
PureTech Health’s earnings are primarily tied to value creation from its drug discovery and development activities and, where applicable, downstream commercialization. Key ways the company can generate revenue include: (1) Product revenue: if a Pu...
PureTech Health Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 29, 2027
Earnings Call Sentiment Positive
The call balanced meaningful clinical and operational progress with financial conservatism and some near‑term funding dependencies. Highlights include positive Phase Ib data for Gallop (LYT‑200) with dose selection and excellent safety, Celea’s Phase III readiness and substantial fundraising progress, a conservative cash runway to end‑2028, reduced operating loss (~27.6% improvement), continued monetization track record (>$1B historically and ~$125M realized from a royalty sale), and Seaport IPO activity — all indicating execution of the hub‑and‑spoke model. Lowlights are the year‑over‑year decline in cash (≈24.4% from 2024 to 2025 and further to ~$248M by March 31, 2026), a swing to consolidated net loss in 2025 driven by the absence of a prior one‑time gain, very low and flat revenues (~$4.7M), and reliance on external fundraising for key Phase III/registration programs which introduces execution and dilution risk. Overall, the positives around portfolio clinical progress, disciplined cost reduction and clear funding plans for key programs outweigh the financial headwinds, though the company remains dependent on successful external financings and monetizations to realize upside.Positive Updates
Positive Phase Ib Data for Gallop (LYT-200)
Top-line Phase Ib data for LYT-200 in relapsed/refractory high‑risk MDS and AML were positive. Safety profile: no dose‑limiting toxicities or myeloid suppression; dose for next study identified at 12 mg/kg. Management has prioritized relapsed/refractory high‑risk MDS and plans FDA engagement toward a potentially registration‑enabling trial, with third‑party capital expected to fund the program (majority external).
Negative Updates
Year‑over‑Year Cash Decline and Reduced Q1 2026 Balance
PureTech-level cash, cash equivalents and short‑term instruments decreased from $366.8M at end‑2024 to $277.1M at end‑2025 (a decline of $89.7M, ≈24.4%). Unaudited cash as of March 31, 2026 was $248.1M, a further decline of ~$29M (~10.5%) from year‑end 2025.
Read all updates
Q4-2025 Updates
Positive
Negative
Positive Phase Ib Data for Gallop (LYT-200)
Top-line Phase Ib data for LYT-200 in relapsed/refractory high‑risk MDS and AML were positive. Safety profile: no dose‑limiting toxicities or myeloid suppression; dose for next study identified at 12 mg/kg. Management has prioritized relapsed/refractory high‑risk MDS and plans FDA engagement toward a potentially registration‑enabling trial, with third‑party capital expected to fund the program (majority external).
Read all positive updates
Company Guidance
Management provided detailed, metric-driven guidance: PureTech held $277.1M (PureTech) / $277.3M (consolidated) at YE‑2025 and ~ $248.1M / $248.2M as of Mar‑31‑2026, and expects operational runway at least through the end of 2028 (inclusive of planned participation in certain fundraises); 2025 revenue was $4.7M (vs $4.8M in 2024), operating loss $98.5M (vs $136.1M in 2024) and net loss $110.1M (vs $27.8M net income in 2024, noting a $151.8M one‑time Seaport gain in 2024). On the portfolio/operational side they plan to progress up to three concept‑stage programs and to nominate up to two development candidates over the next three years, sharpen the hub to a leaner model, and return a greater proportion of future cash generation to shareholders; program milestones include Celea’s financing described as “substantially complete” with a target close by early Q3‑2026 to support a Phase III SURPASS‑IPF start near close, Gallop’s LYT‑200 (12 mg/kg chosen) advancing toward FDA engagement later this year with third‑party fundraising expected to start late 2026 and aim to complete by Q1‑2027, and corporate economics including ~ $125M received to date from a prior Cobenfy royalty sale and an analyst‑based projected value of ~ $160M from Cobenfy rights through 2033.PureTech Health Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
14
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
PureTech Health Technical Analysis
Positive
16.06
Price Trends
16.49
Positive
16.98
Positive
17.02
Positive
Market Momentum
0.09
Negative
60.98
Neutral
93.08
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTCY, the sentiment is Positive. The current price of 16.06 is below the 20-day moving average (MA) of 16.16, below the 50-day MA of 16.49, and below the 200-day MA of 17.02, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 60.98 is Neutral, neither overbought nor oversold. The STOCH value of 93.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRTCY.
PureTech Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $628.13M | -2.21 | -178.58% | ― | 287.93% | -21.91% | |
59 Neutral | $1.62B | -10.89 | -59.21% | ― | -62.28% | 15.36% | |
56 Neutral | $823.69M | -5.39 | -41.33% | ― | 278712.12% | 26.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $416.76M | -0.38 | -31.83% | ― | -3.44% | -312.58% | |
43 Neutral | $142.99M | -1.72 | 44.63% | ― | 3.03% | 57.71% |
* Healthcare Sector Average
PRTCY
PureTech Health
17.10
0.03
0.20%
AUTL
Autolus Therapeutics
2.34
0.84
56.00%
ADCT
ADC Therapeutics
1.14
-1.93
-62.87%
FDMT
4D Molecular Therapeutics
14.67
8.51
138.15%
ABSI
AbSci
8.71
6.32
264.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.